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Abstract: Measurements of immunoglobulins and serum 
free light chains (sFLC) are frequently used in patients 
with monoclonal plasma cell dyscrasia (PCD). For opti-
mum patient care, well-defined performance standards or 
goals for the measured concentrations of immunoglobu-
lins and sFLC are required. Generally, data based on bio-
logical variation is a good and reliable method for setting 
desirable performance standards; this also applies for the 
measurements of paraprotein and sFLC. The benefits of 
this approach are several. Among others, it is independ-
ent of the clinician, and it provides us with information 
about reference change value and index of individuality. 
Several studies on biological variation of both immuno-
globulins and sFLC have been published, and mostly the 
studies are well performed. The studies normally show 
small within- subject biological variation resulting in 
strict analytical goals, which in most cases are difficult 
to meet. Nevertheless, we still need further information 
on biological variation of immunoglobulins and sFLC in 
patients with PCD and in the elderly, which are the main 
target populations for the two measurands. Furthermore, 
to improve data on biological variation of immunoglobu-
lins and sFLC, studies accounting for number of individu-
als, samples, and replicates, as well as time length of the 
studies are needed.
Keywords: biological variation; free light chains; para-
protein; performance standards.
Introduction
Measurements of immunoglobulins and free light chains in 
serum are frequently used when diagnosing and monitoring 
patients with monoclonal plasma cell dyscrasia (PCD), pri-
marily multiple myeloma (MM), AL amyloidosis and mono-
clonal gammopathy of undetermined significance (MGUS) 
[1]. Additionally, baseline measurements of serum free light 
chains (sFLC) are of major prognostic value in virtually every 
PCD, with an abnormal ratio between free κ chains to free 
λ light chains (rFLC) being an adverse prognostic marker. 
Finally, according to the international response criteria, 
measurements of both monoclonal protein (M-protein) and 
sFLC are needed for the response evaluation of MM and AL 
amyloidosis patients after cytoreductive treatment [2].
For clinicians to be able to rely on the measured 
concentrations of the immunoglobulins and sFLC, desir-
able test performances, especially imprecision and bias, 
need to be well defined to fulfill medical needs. For over 
50 years, the setting of analytical quality specifications 
in laboratory medicine has been a matter of discussion 
and debate. Objective standards should always be used in 
laboratory practice to facilitate the provision of optimum 
patient care. In 1999 at the Stockholm Consensus Confer-
ence on quality specifications in laboratory medicine the 
initial proposal for the levels of approach for setting per-
formance standards was made [3]. According to the latest 
consensus statement concerning analytical performance 
specifications: Consensus Statement from the 1st Strategic 
Conference of the European Federation of Clinical Chemis-
try and Laboratory Medicine analytical performance goals 
should be based on a) clinical outcomes, b) components 
of biological variation, or c) state of the art. Depending on 
the measurand, some of the above are more suited than 
others to defining performance goals [4].
A good and reliable, though circuitous method for 
setting desirable performance standards is using data 
based on components of biological variation, using the 
following formulas:
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A ICV % 0.5 CV≤ ∗
2 2
I GBias 0.25 (CV CV )< ∗√ +
ATotal error 1.65 CV Bias, p 0.05< ∗ + <
CVA = analytical variation; CVI = within-subject biological 
variation; CVG = between-subject biological variation.
The advantages to this approach, in the context of 
measurements of immunoglobulins and sFLC testing are 
several. Firstly, it is independent of the clinician’s sense 
of a significant medical change, which is often unreliable 
and shows that clinicians may have a poor understanding 
of sources of test-result variation. Secondly, it minimizes 
the ratio of ‘analytical noise’ to the biological signal. 
Thirdly, it can be applied to most measurands for which 
population-based or subject-specific biological variation 
data can be established. Fourthly, data on biological vari-
ation provides us with more information than just being 
able to set analytical goals; it provides us with the pos-
sibility of calculating reference change value (RCV), the 
difference needed between two measurements in serial 
monitoring to be significantly different, and further allows 
the calculation of the index of individuality (CVI/CVG), 
which gives us valuable information about the usefulness 
of a normal reference interval in the diagnostic setting. 
Limitations of the method are first of all that studies on 
biological variation are consuming to perform. Also, care 
must be exercised in assessing the relevance and valid-
ity of the data [5]. Another problem with the use of data 
on biological variation is the fact that the derived perfor-
mance standards can be very stringent, because homeo-
static control mechanisms are finely adjusted. Current 
technology does not always allow these performance 
goals to be achieved. They should, however, be viewed 
as targets worthy of achievement, for both manufacturers 
and clinical chemists.
There is published data on biological variation for 
both immunoglobulins and sFLC.
Normal immunoglobulins
The biological variation for immunoglobulins has been 
studied many years ago [6–8]. The obtained CVI and CVG 
in the studies are very similar, with only small devia-
tions, and minimal impact on the desirable performance 
standards. Generally, CVI is low, the average values are: 
IgG 4.0%, IgA 4.6%, and IgM 5.0%. CVG is somewhat 
higher, the average values are: IgG 17.4%, IgA 44.8%, and 
IgM 49.9%. The consequence of the small CVI is that the 
desirable performance goals will be very stringent. In 
most cases the analytical goals are difficult to meet, espe-
cially when using reagents with different lot numbers. In 
the studies, however, CVA attained the analytical goals. 
The limitations of the studies are that only relatively 
young (23–48 years), ostensibly healthy individuals were 
investigated. A limited number of individuals were tested 
[9–11] with a balanced ratio between men and women. 
The time length of the studies varies from 1 week, over 
4 weeks to 3–4 months, with 6–10 samples from each 
subject. The performed studies used the analytical tech-
nique that is the current practice in laboratory testing 
to day, which is necessary for correct interpretation of 
data. What is not taken into account in these studies is 
the fact that biological variation of immunoglobulins can 
be altered in patients with PCD. Studies looking at this 
aspect could improve the use of the derived data, pro-
viding both the desirable performance standards, and 
knowledge on the RCV.
Normal serum free light chains
The performed studies on biological variation for sFLC 
measurements are more recent [12, 13]. CVI of sFLC is gen-
erally small compared to the reference interval, at 4.3% 
and 8.1% for κFLC, and 7.6% and 7.0% for λFLC, in the two 
respective studies. The small CVI results in strict analytical 
goals, which can be difficult to attain due to limitations in 
current technology, and the use of an analysis based on 
polyclonal antibodies. CVG for κFLC is 21.0% and 14.1% and 
for λFLC 30.0% and 27.5%, and thus, considerably higher 
than CVI. The number of individuals studied was 18 and 
21, and more females than males were tested. Again, the 
individuals were young (23–54 years) and healthy, though 
Hansen et al. studied the biological variation in patients 
with PCD, namely MGUS and MM. They found comparable 
CVI between healthy individuals and patients with PCD, 
thus, strengthening the use of RCV, and thereby improv-
ing the clinical monitoring of patients with PCD [12]. The 
sampling period of the studies varied from only 5 days to 
over 2 months to 3–4 months, with five to 10 samples taken 
from each subject. The studies were performed using the 
analytical assay from FreeLite® (The Binding Site Group 
Ltd, Birmingham, UK), which presently is the most fre-
quently used assay for analyzing sFLC. The studies were 
performed on two different platforms. Katzmann et  al. 
have assessed the biological variation of sFLC in patients 
with PCD, and involved FLC over 100 mg/L, and found a 
very high CVI of 27.8%, however CVI was determined over a 
5-year period and therefore not surprisingly large. Further, 
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no information about homogeneity of the results was 
presented in the paper, making the result less useful for 
setting performance standards or RCV [14].
Generally, the studies of biological variation of both 
immunoglobulins and sFLC are well performed, though, 
only partly fulfilling the new proposed checklist for criti-
cal appraisal of studies of biological variation [9].
To optimize the use of data on biological variation in 
the setting of desirable performance standards we need 
further information on biological variation in patients with 
PCD and in the elderly, which are the main target popula-
tions for the two measurands. Also, we need to consider 
the number of individuals studied, as well as the time 
length of the studies. Fraser and Harris stated that “The 
components of variation can be obtained from a relatively 
small number of subjects over a reasonably short period of 
time” [10], but this statement stands unexplained and sci-
entifically unsubstantiated. Røraas et al. have looked into 
this issue, and find that the results obtained in studies 
on biological variation depend on the ratio between CVA 
and CVI. A small CVA is vital to gain sufficient power in 
the experiment. In most situations they find that there is 
greater benefit from increasing the number of samples 
from each individual instead of increasing the number 
of individuals. Also there is higher gain by increasing the 
number of samples rather than increasing the number of 
replicates [11]. The ratio between CVA and CVI is small for 
both immunoglobulins and sFLC, and according to the 
calculations of Røraas et al. a powerful study-design for 
assessing biological variation of the two measurands will 
be 20 individuals having taken 10 samples with two repli-
cates, which will provide a power of 1.0, and an acceptable 
confidence interval of 33%. When assessing the biological 
variation in patients with PCD a proper time length of the 
study will be 3–4 weeks, which in my opinion will be long 
enough to investigate the homeostatic set point, and not 
too long, which would risk slight disease progression and 
biasing the results.
In conclusion, setting desirable performance goals 
using data of biological variation is reliable, bearing in 
mind, that when CVI is small, the standards can be hard 
to fulfill, but nevertheless are worth striving for. Further, 
we need reliable data on the biological variation for both 
immunoglobulins and sFLC. New studies meeting the 
above mentioned criteria would be welcomed and neces-
sary if biological variation is to be the optimal approach 
for setting desirable performance goals.
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